Ras Al Khaimah

Researchers are evaluating how eccentric hamstring contractions affect sports performance and quality of life in young male football players with non-contact grade 1 Anterior Cruciate Ligament ACL injuries. This study focuses on athletes aged 19 to 25 years, currently playing in the UAE, who have a recent diagnosis of this specific ACL injury. The aim is to understand if eccentric hamstring exercises can improve knee stability and overall athletic function compared to usual physiotherapy. Participants are randomly assigned to one of two groups one group receives conventional physiotherapy exercises targeting strength, flexibility, and balance around the knee, while the other group receives the same physiotherapy plus custom-tailored eccentric hamstring exercises such as Nordic hamstring curls and leg curls. The treatments are non-invasive and focus on strengthening the hamstrings through controlled muscle lengthening during exercise. During the study, participants will be tested on their sports performance using the Sargent vertical jump test at the start and after three months. Quality of life and psychological well-being will also be assessed using the ACL Quality of Life questionnaire at these times. Researchers will monitor pain, swelling, and knee function throughout the trial, which lasts three months. The study includes regular exercise sessions and follow-up to evaluate the impact of the interventions on participants recovery and performance.

Researchers are evaluating whether a pharmacist-led educational program can reduce the inappropriate use of proton pump inhibitors PPIs among adults aged 18 years and older with potentially unnecessary PPI prescriptions in Ras Al Khaimah. The study aims to see if this intervention can lower PPI use, improve patients quality of life, and reduce healthcare costs by comparing the intervention group to those receiving usual care. The study is interventional and involves education for both patients and physicians to promote evidence-based deprescribing practices. The study has two groups one receives a pharmacist-led educational intervention including brochures, videos, decision aids, and deprescribing algorithms aimed at encouraging appropriate PPI use. The other group continues with standard care without any pharmacist intervention during the six-month period. Physicians in the intervention group also receive educational materials and guidance to support deprescribing. After six months, educational materials will be offered to the control group. Participants will be followed for six months to track changes in PPI use, symptoms related to gastroesophageal reflux disease, quality of life, medication counts, potential adverse effects, attitudes toward deprescribing, and healthcare costs. Assessments include questionnaires such as the Gastroesophageal Reflux Disease Impact Scale and EuroQol 5-Dimension 5-Level survey. Researchers will monitor if patients stop or reduce PPI doses and evaluate cost-effectiveness and quality-adjusted life years gained over the study period.

Researchers are studying the effects of dupilumab treatment on mental health, specifically anxiety and depression symptoms, as well as quality of life in patients with moderate-to-severe atopic dermatitis AD. The study focuses on patients already receiving dupilumab, aiming to observe how this treatment impacts their psychological well-being and life quality over time. Participants will be observed during a 6-month period while continuing their dupilumab therapy as prescribed by their doctors in real-world clinical settings. The study does not administer any treatments but monitors patients who start dupilumab within 30 days before enrollment. The enrollment period for the study will last about 9 months. Throughout the study, participants will complete assessments measuring anxiety and depression levels using the Hospital Anxiety and Depression Scale HADS and quality of life via tools like the Patient-Oriented Eczema Measure POEM and Dermatology Life Quality Index DLQI. Researchers will evaluate changes from baseline to week 24 in these scores and monitor professional and psychological impacts. The study aims to better understand the mental health outcomes of patients receiving dupilumab over six months.